Nathan Fowler
Hematology & Oncology · Houston, TXNPI 1548475650
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $63,436 of the $84,485 with a category attached, or 75.1%. It is spread thinly across 17 manufacturers, the largest accounting for just 15.0%. Reporting peaked in 2020 at $30,631 and has fallen 99.7% since, to $96 in 2025. Among hematology & oncology clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 60 payments — averaging $1408.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Hikma Pharmaceuticals USA$13K
- Karyopharm Therapeutics Inc.$12K
- Gilead$9K
- Merck$8K
- AstraZeneca$6K
- TG Therapeutics, Inc.$6K
- plus $32K from 11 others
Across 75 payments — averaging $8808.43 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Acerta Pharma LLC$301K
- Genentech, Inc.$96K
- Pharmacyclics LLC, An Abbvie Company$66K
- Pfizer$62K
- AbbVie$47K
- Bristol Myers Squibb$35K
- plus $53K from 2 others
What the payments were for
- Consulting fees$63,43675%
- Speaking & faculty fees$6,3367%
- Travel & lodging$12,96715%
- Food & beverage$1,6862%
- Education$610%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Hikma Pharmaceuticals USA | 4 | $12,700 |
| Karyopharm Therapeutics Inc. | 1 | $11,625 |
| Gilead | 11 | $8,887 |
| Merck | 2 | $7,500 |
| AstraZeneca | 1 | $6,444 |
| TG Therapeutics, Inc. | 10 | $5,662 |
| Genentech USA, Inc. | 4 | $5,576 |
| E.r. Squibb & Sons, L.L.C. | 2 | $4,844 |
| Bristol Myers Squibb | 9 | $4,783 |
| Daiichi Sankyo Inc. | 3 | $4,499 |
| Verastem, Inc. | 1 | $4,350 |
| Novartis | 6 | $4,011 |
| Chugai Pharmaceutical Co., Ltd. | 2 | $1,937 |
| Epizyme, Inc. | 1 | $1,500 |
| Genmab U.S., Inc. | 1 | $96 |
| Ipsen Biopharmaceuticals, Inc | 1 | $61 |
| Genentech, Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$84,485 in reported general payments places this provider in the 90th percentile of 838 hematology & oncology providers in Texas.
Other hematology & oncology in Houston
- Devesh PandyaHouston$1.8M
- Elias JabbourHouston$1.3M
- Naval DaverHouston$853K
- Jorge Cortes-FrancoHouston$627K
- Courtney DinardoHouston$478K
- Prithviraj BoseHouston$463K
- Milind JavleHouston$326K
- Loretta NastoupilHouston$309K
- Boyu HuHouston$281K
- Luis CamachoHouston$276K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.